IRIS
NOBILI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.306
AS - Asia 1.949
EU - Europa 1.754
SA - Sud America 671
Continente sconosciuto - Info sul continente non disponibili 351
AF - Africa 46
OC - Oceania 2
AN - Antartide 1
Totale 7.080
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.213
SG - Singapore 1.004
RU - Federazione Russa 896
BR - Brasile 547
CN - Cina 354
IE - Irlanda 325
VN - Vietnam 309
SE - Svezia 199
IT - Italia 154
HK - Hong Kong 73
IN - India 52
AR - Argentina 46
DE - Germania 43
CA - Canada 38
GB - Regno Unito 36
BD - Bangladesh 34
ID - Indonesia 29
MX - Messico 27
EC - Ecuador 22
AT - Austria 18
PL - Polonia 15
PY - Paraguay 14
CO - Colombia 13
IQ - Iraq 13
TR - Turchia 13
ZA - Sudafrica 13
UA - Ucraina 12
JM - Giamaica 10
VE - Venezuela 10
ES - Italia 9
PK - Pakistan 9
FI - Finlandia 7
KE - Kenya 7
MA - Marocco 7
UY - Uruguay 7
LT - Lituania 6
PE - Perù 6
TN - Tunisia 6
BE - Belgio 5
FR - Francia 5
HN - Honduras 5
KR - Corea 5
RO - Romania 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
JP - Giappone 4
MY - Malesia 4
NL - Olanda 4
SA - Arabia Saudita 4
AL - Albania 3
BH - Bahrain 3
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
EG - Egitto 3
EU - Europa 3
JO - Giordania 3
KZ - Kazakistan 3
NP - Nepal 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CR - Costa Rica 2
IR - Iran 2
MN - Mongolia 2
PH - Filippine 2
PR - Porto Rico 2
SY - Repubblica araba siriana 2
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BM - Bermuda 1
BW - Botswana 1
CI - Costa d'Avorio 1
ET - Etiopia 1
GI - Gibilterra 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ME - Montenegro 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PW - Palau 1
RS - Serbia 1
Totale 6.732
Salva come PNG Salva come JPEG
Città #
Singapore 704
San Jose 338
Dublin 325
Princeton 172
Beijing 170
Ashburn 142
Dallas 141
Santa Clara 130
Council Bluffs 115
Ho Chi Minh City 113
Los Angeles 101
Altamura 90
Jacksonville 81
Hanoi 74
Hong Kong 68
Wilmington 56
São Paulo 50
New York 37
Buffalo 34
Redondo Beach 33
Chicago 28
Rio de Janeiro 24
Chandler 22
Moscow 21
Nuremberg 19
The Dalles 17
Norwalk 16
Curitiba 15
Haiphong 15
London 14
Mexico City 14
Chennai 13
Denver 12
Dong Ket 12
Montreal 12
Orem 11
Guayaquil 10
Phoenix 10
St Louis 10
Manchester 9
Mumbai 9
Toronto 9
Brooklyn 8
Munich 8
Porto Alegre 8
San Francisco 8
Johannesburg 7
Milan 7
Thái Bình 7
Vienna 7
Warsaw 7
Belo Horizonte 6
Boston 6
Frankfurt am Main 6
Hangzhou 6
Istanbul 6
Montevideo 6
Nairobi 6
Santa Fe 6
Stockholm 6
Uberlândia 6
Atlanta 5
Bauru 5
Brasília 5
Brussels 5
Charlotte 5
Columbus 5
Fortaleza 5
Guarulhos 5
New Delhi 5
Philadelphia 5
Phủ Lý 5
Salvador 5
Seoul 5
Sorocaba 5
Ankara 4
Brno 4
Buenos Aires 4
Bắc Giang 4
Caracas 4
Da Nang 4
Dhaka 4
Hefei 4
Helsinki 4
Hải Dương 4
José C. Paz 4
Osasco 4
Poplar 4
Recife 4
Rome 4
Romola 4
Santo André 4
São José dos Pinhais 4
Tashkent 4
Amsterdam 3
Aparecida de Goiânia 3
Araraquara 3
Asunción 3
Baghdad 3
Belford Roxo 3
Totale 3.587
Salva come PNG Salva come JPEG
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 851
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 152
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 141
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 114
Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents 111
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 108
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 100
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 97
A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy 96
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: A first insight 96
Cellular pharmacology of gemcitabine 93
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy 92
Efficacy evaluation of plant products in the treatment of erectile dysfunction related to diabetes 92
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 89
Natural compounds for cancer treatment and prevention 87
Druggable targets in pancreatic adenocarcinoma 87
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 83
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 83
Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? 82
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 82
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 82
Chronic inflammation in urothelial bladder cancer 80
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 78
HLA-G 3'UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment 78
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 77
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 77
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 77
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer 76
Specific markers, micro-environmental anomalies and tropism: opportunities for gold nanorods targeting of tumors in laser-induced hyperthermia 76
Prognostic factors in primary and iterative surgery of colorectal liver metastases 75
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 74
PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients 74
Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer 74
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions 73
Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy 72
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 72
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: A pilot study 72
Oxaliplatin plus Raltitrexed in the treatment of patients with advanced colorectal cancer: A phase II study 71
Establishment and characterization of a new spontaneously immortalized ER -/PR -/HER2 + human breast cancer cell line, DHSF-BR16 71
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 70
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 69
Some suggestions from pk/pd principles to contain resistance in the clinical setting—focus on icu patients and gram-negative strains 69
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 69
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 69
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma 69
Vinorelbine in non-small cell lung cancer: Real-world data from a single-institution experience 68
Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? 68
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 68
Proteomic analysis of the cytotoxic effects induced by the organogold(iii) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 68
Postoperative chemotherapy in resected gastric cancer: Results of a single center experience 68
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 68
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, In combination with cisplatin In patients with advanced non-small-cell lung cancer 68
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 67
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(ii) compounds with sulfur and phosphorus donors 67
Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2′-pyridyl)benzimidazole as ligand: Comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives 67
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 65
Size dependent biological profiles of PEGylated gold nanorods 65
Genomic and genetic alterations infuence the progression of gastric cancer 65
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer 64
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 64
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 63
Oxaliplatinum and 5-fluorouracil in protracted infusion in the treatment of advanced colorectal cancer 63
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma 62
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc 62
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 61
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 60
Pharmacogenetics: Implementing personalized medicine 59
Pharmacological strategies for overcoming multidrug resistance 59
Emerging drugs in refractory colorectal cancer 58
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 57
Gold compounds as anticancer agents: Chemistry, cellular pharmacology, and preclinical studies 57
Role of ATP-binding cassette transporters in cancer initiation and progression 56
The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways 56
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 56
Editorial: Multidrug resistance in cancer: Pharmacological strategies from basic research to clinical issues 56
Focus on biochemical and clinical predictors of response to immune checkpoint inhibitors in metastatic urothelial carcinoma: Where do we stand? 55
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge 55
Exploring the biochemical mechanisms of cytotoxic gold compounds: A proteomic study 52
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 51
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer 50
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 48
Increased Expression of VANGL1 is Predictive of Lymph Node Metastasis in Colorectal Cancer: Results from a 20-Gene Expression Signature 48
Maintenance in gastric cancer: New life for an old issue? 47
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 45
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery 43
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer 42
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties 41
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 38
Totale 7.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022213 0 4 3 2 4 0 2 21 28 6 50 93
2022/2023568 98 98 79 1 3 147 68 21 44 6 3 0
2023/2024304 12 27 20 18 12 82 98 0 0 5 8 22
2024/20251.419 103 464 295 11 37 8 43 39 163 65 96 95
2025/20263.847 173 266 471 575 213 146 351 187 964 287 172 42
2026/2027274 130 144 0 0 0 0 0 0 0 0 0 0
Totale 7.080